Although results from the aforementioned studies seem to be fairly consistent, discussion on hepcidin and its role in cardiovascular disease remains controversial, since all performed studies had methodological limitations—either due to small sample size, to a cross-sectional design, to testing in primary-prevention settings and interpretation of results in manifest disease settings, or due to missing adjustment for potential confounders. Here, HAMP is linked to cardiovascular disorder.